Quick Answer
PharmaCyte Biotech, Inc. reported R&D Expense of $438.4 thousand for fiscal year 2025.
PharmaCyte Biotech, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $438.4K | +7.6% |
| 2024 | $407.4K | -13.0% |
| 2023 | $468.5K | -32.2% |
| 2022 | $690.9K | -24.6% |
| 2021 | $916.2K | +204.2% |
| 2020 | $301.2K | -34.5% |
| 2019 | $460.1K | -77.0% |
| 2018 | $2.00M | +69.0% |
| 2017 | $1.18M | -16.0% |
| 2016 | $1.41M | -59.5% |
| 2015 | $3.48M | +974.8% |
| 2014 | $323.5K | — |
| 2013 | $0.00 | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $93.1K | -21.2% | -34.0% |
| October 31, 2025 | $141.1K | +44.7% | +48.3% |
| July 31, 2025 | $95.2K | -0.9% | -19.5% |
| January 31, 2025 | $118.2K | -6.7% | +21.3% |
| October 31, 2024 | $97.5K | +18.8% | +1.5% |
| July 31, 2024 | $96.0K | -8.1% | -24.2% |
| January 31, 2024 | $126.7K | +179.2% | +54.5% |
| October 31, 2023 | $82.0K | -53.9% | -21.5% |
- PharmaCyte Biotech, Inc. showed an increase of +7.6% in R&D Expense compared to the prior fiscal year.
- The most recent figure is from PharmaCyte Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on August 11, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: